PepGen Inc. (PEPG )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PEPG
- Company PepGen Inc.
- Price $2.85
- Changes Percentage 18.26
- Change 0.44
- Day Low $2.44
- Day High $2.88
- Year High $7.8
- Year Low $1.01
- Market Cap $124,504,578
- Price Avg 50 EMA (D) $1.76
- Price Avg 200 EMA (D) $3.95
- Exchange NASDAQ
- Volume 296,115
- Average Volume 977,352
- Open $2.48
- Previous Close $2.41
- EPS -1.75
- PE -1.03
- Earnings Announcement 2026-08-06 04:00:00
- Shares Outstanding $69,169,210
Company brief: PEPGEN INC. (PEPG )
- Healthcare
- Biotechnology
- Dr. James G. McArthur Ph.D.
- https://www.pepgen.com
- US
- N/A
- 05-06-2022
- US7133171055
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.